Sara Hurvitz
Impact in
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
Papers in
- Oncology 157
- HER2/EGFR in Cancer Research 93
- Cancer Treatment and Pharmacology 45
- PARP inhibition in cancer therapy 16
-
- Advanced Breast Cancer Therapies 82
- Co-authors
- Hope S. Rugo (43 shared papers)Johannes Ettl (17 shared papers)Lida A. Mina (7 shared papers)Anthony Gonçalvès (11 shared papers)Young‐Hyuck Im (5 shared papers)Ruben G.W. Quek (9 shared papers)Jennifer Keating Litton (8 shared papers)Joanne Lorraine Blum (5 shared papers)
- Journals
- Annals of Oncology (55 papers)Clinical Cancer Research (21 papers)Journal of Clinical Oncology (15 papers)The Lancet Oncology (11 papers)Breast Cancer Research and Treatment (11 papers)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Sara Hurvitz
266 papers receiving 22.4k citations
Sara Hurvitz's Hit Papers
Peers
Comparison fields: 5 of 142
- Oncology 12.6k
- Cancer Research 4.2k
- Pulmonary and Respiratory Medicine 7.9k
- Genetics 1.6k
- Radiology, Nuclear Medicine and Imaging 2.8k
Countries citing papers authored by Sara Hurvitz
This map shows the geographic impact of Sara Hurvitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Hurvitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Hurvitz more than expected).
Fields of papers citing papers by Sara Hurvitz
This network shows the impact of papers produced by Sara Hurvitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Hurvitz. The network helps show where Sara Hurvitz may publish in the future.
Co-authors
The 25 scholars most cited alongside Sara Hurvitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 269 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation Hit paper breakdown → | 2018 | 1670 |
| 2 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Hit paper breakdown → | 2019 | 1575 |
| 3 | Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2021 | 1197 |
| 4 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Hit paper breakdown → | 2021 | 993 |
| 5 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2019 | 971 |
| 6 | Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Hit paper breakdown → | 2018 | 784 |
| 7 | Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer Hit paper breakdown → | 2019 | 746 |
| 8 | Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2022 | 674 |
| 9 | Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial Hit paper breakdown → | 2020 | 482 |
| 10 | Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Hit paper breakdown → | 2022 | 472 |
| 11 | Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 457 |
| 12 | Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial Hit paper breakdown → | 2020 | 428 |
| 13 | 2017 | 415 | |
| 14 | 2017 | 414 | |
| 15 | 2011 | 344 | |
| 16 | 2013 | 336 | |
| 17 | Cycling cancer persister cells arise from lineages with distinct programs Hit paper breakdown → | 2021 | 334 |
| 18 | NCCN Guidelines® Insights: Breast Cancer, Version 4.2023 Hit paper breakdown → | 2023 | 317 |
| 19 | 2020 | 311 | |
| 20 | 2009 | 281 |
About Sara Hurvitz
Sara Hurvitz is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 269 papers that have together received 22.9k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (93 papers), Advanced Breast Cancer Therapies (82 papers), Cancer Treatment and Pharmacology (45 papers), Breast Cancer Treatment Studies (30 papers), Monoclonal and Polyclonal Antibodies Research (30 papers), PARP inhibition in cancer therapy (16 papers), PI3K/AKT/mTOR signaling in cancer (13 papers) and BRCA gene mutations in cancer (13 papers). The work is most often cited by research in Oncology (12.6k citations), Cancer Research (4.2k citations), Pulmonary and Respiratory Medicine (7.9k citations), Genetics (1.6k citations) and Radiology, Nuclear Medicine and Imaging (2.8k citations). Sara Hurvitz has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Hope S. Rugo, Johannes Ettl, Lida A. Mina, Anthony Gonçalvès, Young‐Hyuck Im, Ruben G.W. Quek, Jennifer Keating Litton, Joanne Lorraine Blum, Aditya Bardia and Wolfgang EIERMANN. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research, Journal of Clinical Oncology, The Lancet Oncology and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.